Talphera (TLPH) Projected to Post Earnings on Wednesday

Talphera (NASDAQ:TLPH) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Talphera to post earnings of ($0.1250) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Talphera (NASDAQ:TLPH) last announced its earnings results on Thursday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. On average, analysts expect Talphera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Talphera Price Performance

NASDAQ TLPH opened at $1.24 on Monday. The business’s fifty day moving average is $1.03 and its 200-day moving average is $0.67. The stock has a market capitalization of $57.80 million, a price-to-earnings ratio of -3.10 and a beta of 0.15. Talphera has a one year low of $0.38 and a one year high of $1.45.

Analyst Ratings Changes

TLPH has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, October 8th. Wall Street Zen upgraded Talphera to a “hold” rating in a research note on Saturday, November 1st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Talphera presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.